|
|
Learning Objective:
By the end of the presentation the participants will be able to:
1. Understand the importance of hepatitis vaccination in various substance abuse treatment settings
2. Become familiar with the SAMHSA pilot hepatitis vaccination program
Background:
Substance abuse treatment settings can provide a comprehensive therapeutic milieu for the treatment of opioid addiction including primary medical care, psychosocial counseling, vocational rehabilitation, HIV and hepatitis testing /counseling. Patients, coinfected with HIV and HCV are at high-risk for serious liver disease through the development of end stage liver disease due to super-infection with either hepatitis B or hepatitis A. Prevention of hepatitis B superinfection or hepatitis A super infection, through the vaccination of coinfected individuals is recommended by the CDC. Concomitant with vaccination is the education of patients on hepatitis B infection, hepatitis A infection, and vaccination. Substance abuse treatment provides a unique setting to perform hepatitis vaccinations to reduce disease comorbidities
Setting:
Opioid Treatment Programs, HIV primary care with buprenorphine certified physicians and SAMHSA supported Minority AIDS Initiative (MAI) grantees
Population e.g. API Youth, MSM, IDU:
minority individuals with HIV and HCV coinfections
Project Description:
The pilot program supports the purchase, distribution and vaccination of HIV/HCV coinfected individuals for the prevention of serious liver disease. Vaccination is with Twinrix, the only combination hepatitis A and hepatitis B vaccine, occurring with a standard 3-dose schedule by intramuscular injection, given on a 0-, 1- and 6-month schedule as part of the substance abuse treatment program
Results/Lessons Learned:
Outcomes measured are the number of individuals who complete the vaccine series as well as the vaccine efficacy in varying substance abuse treatment settings.
See more of H6 - Models of Hepatitis Vaccination in Substance Abuse Treatment Settings
See more of The 2005 National Viral Hepatitis Prevention Conference